Home MagAssist Medical Recognized as Suzhou New District's 2025 High-Growth Innovative Enterprise Amid IPO Filing

MagAssist Medical Recognized as Suzhou New District's 2025 High-Growth Innovative Enterprise Amid IPO Filing

Apr 29, 2026 20:16 CST Updated 20:16
magAssist

Developer of Extracorporeal Artificial Heart Devices

图片



 
Suzhou High-tech Zone Investment Promotion Conference 

High-Growth Innovative Enterprises of 2025

At the recently held Suzhou New District Investment Promotion Conference, magAssist was awarded the title of "High-Growth Innovative Enterprise of 2025." This title is mainly granted to enterprises with high specialization, strong innovation capabilities, and great development potential. The award is a full affirmation of magAssist's comprehensive strength and independent innovation capability.

Image

As a company rooted in the life support equipment field in Suzhou New District, magAssist has always focused on the research, development, production, and promotion of products such as extracorporeal artificial hearts, interventional artificial hearts[1], and ECMO[1]. The company maintains high-intensity R&D investment, with over 400 self-developed patent applications cumulatively. It has achieved key breakthroughs in core technologies such as full magnetic levitation, mechatronics integration, and fluid mechanics optimization, realizing independent control and steadily advancing the transformation of technological innovation into products.

Image

The recognition as a high-growth innovative enterprise highlights magAssist's solid foundation in mastering core technologies, transforming scientific and technological achievements, and building innovative teams. In the future, magAssist will continue to uphold the mission of "Guarding Life with Technology," focus on tackling core technologies, accelerate the industrialization process, resonate with regional development, and contribute to the high-quality development of the healthcare industry.


[1] The product information of the new generation extracorporeal membrane oxygenation system (BreathMo®) and minimally invasive interventional artificial heart (NoykAssist®) is for research and exchange only. It has not been approved by the National Medical Products Administration and has not been sold in any country or region.


-END-


图片